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Abstract
Introduction. Left ventricular hypertrophy (LVH) is one of the most common cardiovascular risk factors in patients under-
going haemodialysis (HD). Although standard ECG can help to identify patients at greater risk of LVH, its prognostic value 
in haemodialysed patients is uncertain. This study aimed to evaluate currently used ECG criteria for LVH in patients on 
renal replacement therapy.
Material and methods. A group of 90 patients, who were undergoing qualification to renal transplantation, were 
included in the study. Every patient underwent 12-lead ECG and transthoracic echocardiography. Patients with any 
conduction disorders were excluded from the study. Finally, the study group consisted of 76 patients (21 women, mean 
age 53.1 ± 14.4 years).
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Results. LVH was diagnosed by echocardiography in 39 patients (51%, 27 men and 12 women). Only three out of six 
tested criteria showed satisfactory performance for LVH diagnosis in HD patients: the sum of S V3 and R aVL > 28 mm 
in men, and > 20 mm in women (area under curve [AUC] 68%, 95% confidence interval [CI] 56–80); the sum of S V1 and 
R V5 or V6 > 35 mm (AUC 63%, 95%CI 50–76); and the sum of SV2 and RV5 or V6 > 45 mm (AUC 63%; 95%CI 50–75).
Conclusions. The present ECG diagnostic criteria for LVH are of very limited value in patients undergoing HD. Further 
studies should be performed to establish new ECG criteria for this group of patients. In the meantime, echocardiography 
should be recommended as the most precise diagnostic routine test to evaluate HD patients for LVH.
Key words: left ventricular hypertrophy, electrocardiography, end-stage renal disease, haemodialysis, renal  
replacement therapy
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Introduction
Cardiovascular complications are the leading cause of 
mortality and morbidity in patients with end-stage renal 
disease (ESRD). It is well known, that the prevalence 
of cardiovascular disease (CVD) is very high already at 
the beginning of renal replacement therapy (RRT) even 
begins [1]. Apart from the traditional risk factors for 
CVD, there is growing evidence that these patients are 
at increased risk as a result of potential specific uraemic 
risk factors that are responsible for the presence and 
progression of CVD. These include volume overload, 
hypertension, anaemia, abnormal calcium-phosphate 
metabolism, accumulation of uraemic toxins, and the 
chronic inflammatory process [2].
LVH, which is present in 50% to 70% of patients un-
dergoing HD [3], is an independent risk factor of CVD and 
sudden cardiac death (SCD). Standard electrocardiography 
is a widely used screening method for diagnosing LVH [4]. 
However, data on the diagnostic value of ECG in haemodia-
lysed patients is limited [5, 6]. This study aimed to assess 
the diagnostic value of currently used electrocardiograp-
hic (ECG) criteria for LVH diagnosis in patients with ESRD 
undergoing HD.
Material and methods
A group of 90 consecutive patients (21 women, 69 men, 
mean age 53.7 ± 14.3 years) with ESRD, who were un-
dergoing HD, and who were hospitalised in the cardiology 
department for a cardiovascular assessment prior to renal 
transplantation, were included in the study. All of them 
underwent a detailed clinical evaluation i.e. standard 12-
lead ECG, transthoracic echocardiography focused on left 
ventricular morphology and function, exercise ECG test 
when possible, and exercise perfusion heart scintigraphy 
(SPECT). Subsequently, all subjects with LV wall motion 
abnormalities at echocardiography or abnormal exercise 
tests underwent coronary angiography. Patients with QRS 
duration ≥ 120 ms (due to right or left bundle branch 
block, interventricular conduction delay or after pacemaker 
implantation) were excluded from further analysis. Thus, 
the final study group consisted of 76 patients (21 female, 
55 male, mean age 53.1 ± 14.4 years), as set out in Tab-
le 1. This study was approved by our Institutional Review 
Board. All patients provided written informed consent to 
participate in this study.
Electrocardiography
All patients underwent a standard rest 12-lead ECG. Exami-
nations were performed with a Spacelabs Cardio Express 
Table 1. Clinical characteristics of 76 patients with end-stage 
renal disease (ESRD) treated with haemodialysis
Parameter Total 
N = 76
Aetiology of ESRD, N [%]:
• glomerulonephritis
• diabetes mellitus
• polycystic kidney disease
• other
27 (35.5)
20 (26.3)
12 (15.8)
17 (22.4)
Time of HD, median (months) 24 (2–228)
Coronary artery disease, N [%] 33 (43)
Hypertension, N [%] 71 (96)
Heart failure (HF), nN [%]:
• HF-PEF
• HF-MEF
• HF-REF
18 (23)
8
8
2
Diabetes mellitus, N [%]:
• type 1
• type 2
24 (31)
7
17
HD — haemodialysis; HF-PEF — heart failure with preserved ejection fraction; HF-MEF — heart 
failure with midrange ejection fraction; HF-REF — heart failure with reduced ejection fraction
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SL6 device. The ECGs were recorded at speed of 25 mm/s 
and a standardised calibration of 1 mV/cm. 29 patients 
underwent the ECG on the day of the HD, just before the 
procedure, while 47 patients underwent the ECG on the day 
after the HD. Patients with RBBB, LBBB, IVCD or patients 
after pacemaker implantation were not included in the cur-
rent analysis. Standard 12-lead ECG tracings were analysed 
by the same investigator for LVH using electrocardiographic 
LVH criteria according to European Society of Cardiology 
(ESC) and Polish Society of Cardiology guidelines [7], as 
set out in Table 2. The QRS amplitude was measured by 
the same investigator, manually.
Echocardiography
iE 33 and EPIQ 7 Philips (Andover, Md., USA) systems 
with a sector transducer with bandwidths of 2.5–3.5 MHz 
were used for transthoracic echocardiographic examina-
tions. Patients were placed in the left-lateral decubitus 
position, with continuous monitoring of a single ECG lead. 
Echocardiographic images were interpreted by an experi-
enced physician according to the recommendations of the 
guidelines of the European Association of Cardiovascular 
Imaging [8]. Interventricular septum (IVS) and posterior 
wall (PW) thickness were measured at late diastole with 
two-dimensional imaging in the long parasternal axis view. 
Left ventricle dimensions were recorded by placing the 
ultrasound beam perpendicularly to its long axis. Measure-
ments were performed in 2D visualisation and in M-Mode 
presentation. Left ventricular mass (LVM) was calculated 
according to the formula proposed by Devereux [9]: LVM 
[g] = 1.04 [(IVS [cm] + LVDd [cm] + PW [cm])3 – LVDd3] – 
13.6. The LVM index (LVMI) was calculated as LVM divided 
by body surface area (BSA). We diagnosed LVH when the 
LVMI exceeded 109 g/m2 in women and 132 g/m2 in men 
[8]. Echocardiographic examinations were performed in 
31 patients just before the HD, and in 45 patients the day 
after the HD.
Table 2. Current diagnostic electrocardiographic criteria of left 
ventricular hypertrophy
Criterion
R aVL > 1.1 mV (11 mm)
R I + S in III > 2.5 mV (25 mm)
R V5 or V6 > 2.6 mV (26 mm)
S V1 + R V5 or V6 > 3.5 mV (35 mm)
S V2 + R V5 or V6 > 4.5 mV (45 mm)
S V3 + R aVL > 2.8 mV (28 mm) men; S V3 + R aVL > 2.0 mV 
(20 mm) (women)
Statistical analysis
Descriptive statistics for quantitative data were presen-
ted as means ± standard deviations or medians with 
ranges, when appropriate. Qualitative data were shown 
as counts and percentages. Between-group comparisons 
for qualitative data were performed using Chi-square test 
or Fisher’s exact test, depending on the expected counts. 
For quantitative variables, t-test with Welch correction or 
Mann-Whitney tests were used, depending on the group 
size and normality of distributions. Receiver operating 
curves (ROC) were used to assess the performance of ECG 
indices for the diagnosis of LVH. For significant predictors 
of LVH, we assessed sensitivity and specificity based on 
currently accepted ECG criteria. All reported results are 
based on two-sided statistical tests. Effects were consi-
dered significant at a p-value of less than 0.05. Statistical 
analyses were performed using R software (R Core Team, 
2017 version 3.4.2).
Results
The clinical characteristics of the final study group with 
ESRD undergoing HD are set out in Table 1. The mean age 
was 53.1 ± 14.4 years and 27.6% were women. ESRD had 
resulted from glomerulonephritis in 35.5% of subjects, from 
diabetes mellitus in 26.3% of subjects, and from polycystic 
kidney disease in 15.8% of subjects. Hypertension requiring 
medical therapy was present in 71 patients (96%), and 33 
patients (43%) suffered from coronary artery disease. LVH 
was diagnosed by echocardiography in 39 patients (51.3%), 
27 men (69.2%) and 12 (30.8%) women. The clinical cha-
racteristics based on LVH presence are set out in Table 3. 
Statistically significant differences were BMI which was 
lower in the group of patients with LVH, and the mean time 
of HD which was shorter in the LVH group.
ECG for the diagnosis  
of left ventricular hypertrophy
Table 4 shows ROC analysis of six electrocardiographic 
criteria proposed by ESC for LVH diagnosis. Only three out 
of six tested criteria showed satisfactory performance for 
LVH diagnosis in HD patients, with a lower limit of AUC 
confidence interval exceeding 50% (Table 5, Figure 1). The 
sum of the amplitude of R wave in aVL with the amplitude 
of S wave in V3 showed the highest significant predictive 
power (AUC 68%, 95% CI 56–80).
Three criteria: 1) the amplitude of R in aVL (AUC 61%; 
95% CI 48–74); 2) the sum of the amplitude of R wave in 
lead I and amplitude of S wave in lead III (AUC 57%; 95%CI: 
43–70); and 3) the amplitude of R wave in lead V5 or lead 
V6 (AUC 59%; 95% CI: 46–72) were found to be not statisti-
cally significant for LVH diagnosis. Eventually, using current 
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ECG criteria, LVH was diagnosed in only 12 of 39 subjects 
with echocardiographically detected LVH.
Discussion
In this study, we assessed the effectiveness of ECG as a cli-
nical tool reflecting LVH. Kidney Disease Outcomes Quality 
Initiative (K/DOQI) guidelines recommend the recording of 
an ECG in every patient at the initiation of RRT, and annually 
thereafter [9]. In ESRD patients, LVH detected by ECG or 
echocardiography is the most common manifestation of 
cardiovascular disease and strongly predicts cardiovascular 
morbidity and mortality [6].
Therefore, ECG is the common tool which can be used 
to select patients with an increased cardiovascular risk. 
However, there is very limited data regarding the diagnos-
tic value of standard ECG criteria in patients with ESRD 
undergoing HD [5, 6]. It is well known that fluid overload 
and electrolyte imbalance can affect QRS voltage, and thus 
the interpretation of standard ECG. In our study, LVH was 
diagnosed in 39 patients (51%). Only 12 (30.8%) patients 
in this group had diagnosed LVH in ECG. Three out of six 
proposed ECG criteria were found to have a significant 
predictive power in ROC analysis. Of these three, the most 
useful for LHV diagnosis in HD patients (AUC 68% 95 CI 
56–80), was found to be the sum of sV3 with RaVL. Im-
portantly, current cut-off values of ECG criteria were found 
to be suboptimal.
Our study had several limitations. Because the num-
ber of patients was relatively small, the clinical outcomes 
Table 3. Clinical characteristics of patients according to left ventricular hypertrophy
Parameter LVH (+) 
N = 39 (51.3)
LVH (–) 
N = 37 (48.7)
p value
Sex M/F, n(%) 27 (69.2)/12(30.8) 28 (75.7)/9(24.3) NSa
Age, years 51.4 ± 13.2 54.8 ± 15.5 NS
BMI [kg/m2] 23.7 (17.2–35.5) 25.3 (18.6–33.6) 0.026b
Time of HD, median [months] 18 (2–228) 31 (2–204) 0.017
CAD, N [%] 15 (38.5) 18 (48.6) NSa
Hypertension, N [%] 39 (100.0) 32 (86.4) NSc
Aetiology of ESRD N [%]:
• glomerulonephritis
• diabetes mellitus
• polycystic kidney disease
• other
10 (25.6)
11 (28.2)
3 (7.7)
15 (38.5)
15 (40.5)
9 (24.3)
9 (24.3)
4 (10.9)
0.014a
LVM [g] 289.4 ± 69.5 195.5 ± 42.0 < 0.0001
LVM [g]:
• M
• F
318.0 ± 58.0
223.5 (169.4–345.0)
210.4 ± 33.9
165.4 (105.6–177.2)
< 0.0001
< 0.0001b
LVMI [g/m2] 146.7 (112.2–235.5) 105.1 (66.7–129.2) < 0.0001b
LVMI [g/m2]:
• M
• F
155.6 (132.2–235.5)
129.7 (112.2–213.5)
112.1 (71.5–129.2)
83.8 (66.7–107.9)
< 0.0001 b
< 0.0001 b
aChi-square test, bMann-Whitney test, cFisher’s exact test; all remaining comparisons were conducted using t-tests with Welch correction, LVH — left ventricular hypertrophy; M — male; F — female; NS — not 
significant; BMI — body mass index; N — number of patients; HD — haemodialysis; CAD — coronary artery disease; ESRD — end-stage renal disease; LVM — left ventricular mass; LVMI — left ventricular mass 
index
Table 4. Receiver operating curves analysis of electrocardiograp-
hic (ECG) criteria in the diagnosis of left ventricular hypertrophy 
in patients with end-stage renal disease
ECG criterion AUC [%] 95% Cl p
R aVL 61 48–74 NS
R I + S III 57 43–70 NS
R V5 or V6 59 46–72 NS
S V1 + R V5 or V6 63 50–76 0.047
S V2 + R V5 or V6 63 50–75 0.036
S V3 + R aVL 68 56–80 0,003
NS — not significant; AUC — area under curve; CI — confidence interval
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may not be generalisable to the whole population. Some 
authors have suggested that ECG should be interpreted 
in the context of the recording time, in relation to the HD 
treatment, fluid overload and electrolyte status, because 
these changes have been shown to affect ECG wave am-
plitude, which can determine the diagnosis of LVH [10].
In our study, 29 patients underwent the ECG just 
before the HD, while 47 patients underwent the ECG the 
day after the HD. Also, echocardiographic examinations 
were performed in 31 patients just before the HD, and in 
45 patients the day after the HD. Therefore, we did not 
find any statistically significant difference in diagnosing 
LVH in both groups.
Conclusions
The present ECG criteria for LVH are of very limited value 
in the group of patients undergoing HD. A further study on 
a large group of patients should be performed to established 
new cut-off points for ECG criteria for patients requiring HD.
In the meantime, it appears that echocardiography sho-
uld be recommended as the most precise routine diagnostic 
method to evaluate for the presence of LVH.
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Table 5. Diagnostic value of current electrocardiographic criteria in the diagnosis of left ventricular hypertrophy in patients with end-stage 
renal disease
Criterion Value 
[mm]
Current cut-off
Sensitivity [%] Specificity [%] PPV [%] NPV [%]
S V1 + R V5 or V6 [mm] 35 8 97 75 53
S V2 + RV5 or V6 [mm] 45 8 100 100 53
S V3 + aVL M > 28 
F > 20
14 97 83 54
PPV — positive predicitive value; NPV — negative predicitive value
Figure 1A–C. Receiver operating curves for all statistically significant electrocardiographic parameters in the diagnosis of left ventricular 
hypertrophy in patients with end-stage renal disease; AUC — area under curve; CI — confidence interval
95% CI: 50–75 95% CI: 56–80 95% CI: 50–76
A B C
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Streszczenie
Wstęp. Przerost mięśnia lewej komory (LVH) jest głównym czynnikiem ryzyka powikłań sercowo-naczyniowych u pacjen-
tów leczonych powtarzanymi zabiegami hemodializ (HD). Choć rutynowo wykonywany zapis elektrokardigraficzny (EKG) 
może pomóc w identyfikacji chorych z LVH, to jego wartość diagnostyczna wśród pacjentów poddawanych zabiegom 
HD pozostaje niepewna. Celem badania była weryfikacja przydatności diagnostycznej stosowanych obecnie kryteriów 
elektrokardiograficznych LVH w grupie pacjentów leczonych nerkozastępczo.
Materiał i metody. Do badania włączono 90 chorych kwalifikowanych do zabiegu przeszczepienia nerki. U każdego 
pacjenta wykonano 12-odprowadzeniowy zapis EKG oraz przezklatkowe badanie echokardiograficzne. Z badania wyklu-
czono chorych z zaburzeniami przewodzenia śródkomorowego rozpoznawanymi w badaniu EKG. Ostatecznie do badania 
włączono 76 pacjentów (21 kobiet, średni wiek 53,1 ± 14,4 roku).
Wyniki. W badaniu echokardiograficznym LVH rozpoznano u 39 chorych (51%, 27 mężczyzn i 12 kobiet). Tylko 3 z 6 
ocenianych kryteriów okazały się istotne statystycznie w diagnostyce LVH u hemodializowanych chorych. Były to: suma 
załamka S w odprowadzeniu V3 oraz załamka R w odprowadzeniu aVL przekraczająca 28 mm u mężczyzn i 20 mm 
u kobiet (pole pod krzywą [AUC] 68%, 95-proc. przedział ufności [CI] 56–80), suma załamka S w odprowadzeniu V1 
oraz załamka R w odprowadzeniu V5 lub V6 przekraczająca 35 mm (AUC 63%, 95%Cl 50–76), a także suma załamka S 
w odprowadzeniu V2 i załamka R w odprowadzeniu V5 lub V6 przekraczająca 45 mm (AUC 63%; 95%Cl 50–75).
Wnioski. Stosowane obecnie kryteria elektrokardiograficze LVH mają niską wartość diagnostyczną w grupie chorych 
hemodializowanych. Należy przeprowadzić dalsze badania w celu ustalenia nowych kryteriów elektrokardiograficznych 
LVH w tej grupie chorych. Wydaje się, że badanie echokardiograficzne jest najbardziej dokładne w wykrywaniu LVH i to 
ono powinno być obecnie wykorzystywane do diagnostyki LVH w grupie chorych poddawanych HD.
Słowa kluczowe: przerost mięśnia lewej komory, elektrokardiografia, schyłkowa niewydolność nerek, hemodializy,  
terapia nerkozastępcza
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